Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$65.68 USD

65.68
3,456,884

-1.42 (-2.12%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (59 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bruker (BRKR) Banks on End Market Growth Amid Macro Headwinds

by Zacks Equity Research

Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.

Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy

by Zacks Equity Research

Charles River (CRL) signs an agreement with AAVantgarde to produce GMP plasmid DNA for Stargardt's disease program.

Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

DexCom (DXCM), Abbott to Launch First FDA Cleared OTC CGMs

by Zacks Equity Research

Dexcom (DXCM) and Abbott are set to launch their first FDA-approved over-the-counter CGMs, Stelo and Lingo & Libre Rio, respectively, in the United States this summer.

Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi

by Zacks Equity Research

Tandem Diabetes (TNDM) unveils survey results of the new Tandem Mobi insulin delivery system, underscoring its potential to significantly enhance the quality of life for people with diabetes

DexCom's (DXCM) G6 CGM System Combines With AID in Netherlands

by Zacks Equity Research

DexCom (DXCM) announces expansion of its AID partnership in the Netherlands to offer an easier diabetes management experience.

Insulet (PODD) Unveils Key Achievements for the Omnipod 5 System

by Zacks Equity Research

Insulet (PODD) debuts the Omnipod 5 AID system in France and announces new updates for the U.S. markets.

Why DexCom (DXCM) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Asensus Surgical (ASXC) Inks a Merger Agreement With KARL STORZ

by Zacks Equity Research

KARL STORZ is set to acquire all of the outstanding shares of Asensus Surgical (ASXC) for $0.35 per share in cash, making Asensus a subsidiary of KARL STORZ.

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

DexCom's (DXCM) G7 CGM System Now Connects to Apple Watch

by Zacks Equity Research

DexCom (DXCM) announces the direct connectivity of its G7 CGM system to Apple Watch for users in the United States, the UK, and Ireland.

DexCom (DXCM) Declines on Potential Competition for Stelo (revised)

by Zacks Equity Research

DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.

DexCom (DXCM) Declines on Potential Competition for Stelo

by Zacks Equity Research

DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor

by Zacks Equity Research

Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM.

Why DexCom (DXCM) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio Now

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Should iShares Russell Mid-Cap Growth ETF (IWP) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWP

Haemonetics (HAE) Banks on Plasma Arm Growth Amid Rising Costs

by Zacks Equity Research

Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.

Here is Why Growth Investors Should Buy DexCom (DXCM) Now

by Zacks Equity Research

DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Ecolab (ECL) Q1 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Ecolab's (ECL) robust performance across the majority of its segments drives its first-quarter sales despite business challenges.

QIAGEN (QGEN) Q1 Earnings Top Estimates, Margins Expand

by Zacks Equity Research

QIAGEN (QGEN) Q1 results are driven by solid growth in consumables and ongoing higher instruments placements.

DexCom, Inc. (DXCM) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

DexCom (DXCM) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here's Why You Should Buy Bruker (BRKR) Stock Right Now

by Zacks Equity Research

Bruker's (BRKR) strong potential across the NANO and BioSpin segments bodes well for investors.